Agilent Technologies (A) Appoints Mikael Dolsten Named to its Board
- Wall St ends up with Goldman; Dow posts biggest weekly rise since June
- Goldman Sachs (GS) Smashes Analyst 3Q Views on Robust M&A and Underwriting Activity
- Tesla (TSLA) Stock: Jefferies Raises Price Target on Higher Capacity Ramp and Sustained Demand, Berlin Giga Will Set New Design and Assembly Standards Says Analyst
- Food, fuels lift U.S. import prices in September
- SEC to Allow First Ever Bitcoin (BTC) ETF - Report
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Mikael Dolsten, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer Inc. has been elected to Agilent’s board of directors, effective Sept. 21, 2021.
Dr. Dolsten brings 30 years of pharma experience to the Agilent board. During his career, he has led teams that have selected more than 150 candidate drugs entering human clinical studies for the treatment or prevention of human disease and has been involved in advancing more than 30 drugs and vaccines to approval. Most recently, he co-led Pfizer’s recent collaboration with BioNTech to develop COMIRNATY® (COVID-19 vaccine, mRNA).
“Mikael’s outstanding scientific, medical and research background makes him a valuable addition to the Agilent board,” said Mike McMullen, Agilent president and CEO. “His leadership in small-molecule medicines, biotherapeutics, gene therapies and vaccines will be a key asset for Agilent moving forward. We look forward to working with Mikael and benefitting from his experience in these strategically important areas.”
“We’re pleased to welcome Mikael to the Agilent board,” said Koh Boon Hwee, chair of the Agilent board. “His deep background in pharma and successful leadership of critical research initiatives at Pfizer will add an important perspective to our work at Agilent.”
Dr. Dolsten has served in a variety of roles for Pfizer since 2009 including chief scientific officer, president of R&D and senior vice president and division president, Biotherapeutics Research and Development. He has served in his current role as president of Worldwide Research, Development and Medical since 2019, where he leads a team of over 8,000 scientists and oversees all global research operations across six therapeutic areas for Pfizer. In addition, during his career, Dr. Dolsten has served in research leadership positions for Wyeth Pharmaceuticals, Boehringer Ingelheim, AstraZeneca and Pharmacia & Upjohn.
He has published more than 150 scientific articles and book reviews and is an active leader in the scientific community. He currently serves as co-chair of the National Institutes of Health (NIH)-Accelerating Medicines Partnership program and an executive committee member of the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative coordinating a national science strategy in response to COVID-19. Dr. Dolsten also serves on the Science and Regulatory Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He has been an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council and was recently elected as Foreign Member of The Royal Swedish Academy of Engineering Sciences.
Dr. Dolsten has served as an advisor to the Obama administration for regulatory sciences, to then Vice President Joe Biden in the Cancer Moonshot initiative and to the UK Government for the 2021 G7 Summit.
He is a member of the board of directors for Karyopharm Therapeutics, as well as the board at Vimian Group.
Dr. Dolsten received both his medical degree and doctorate from Lund University in Sweden where he was also selected as an adjunct professor in immunology.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Tesla (TSLA) To Roll Out FSD Beta 10.3; Pushes Software to Investor with Poor 'Safety Score'
- Spirit AeroSystems (SPR) Statement on Possible Flawed Parts from MPS
- Agilent Technologies (A) Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
Create E-mail Alert Related CategoriesBoard Changes, Corporate News
Related EntitiesTwitter, Barack Obama
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!